Biotechnology medicines company Amgen, Inc. (AMGN) had its earnings estimates and price target raised by analysts at Leerink Swan on Wednesday, as the company’s T-VEC product continues to perform well in clinical studies.
The analysts maintain a “Market Perform” rating on AMGN and now see shares reaching $99. This target suggests a 7% upside to Tuesday’s closing price of $92.40.
Amgen shares were up $1.81, or +1.92%, during morning trading on Wednesday. The stock is up +39.95% over the past twelve months.
The Bottom Line
Shares of Amgen (AMGN) have a dividend yield of 2.00% based on Wednesday’s intraday trading price of $94.21 and the company’s annualized dividend payout of $1.88 per share.
Amgen, Inc. (AMGN) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.